Once daily Tedizolid has a similar adverse effect profile as that of twice daily linezolid in treating acute bacterial skin infections and skin structure infections. This was found out after a phase 3 study called the TR-701 FA vs Linezolid for the treatment of acute bacterial skin and skin structure infections, published online June 6 in Lancet Infectious Disease.
Tedizolid could become a useful option for treating acute bacterial skin infection and skin structure infections.
Another evidence provided for the non inferiority of short term treatment of bacterial skin and skin structure infections with a new drug is seen in ‘ Moran and colleagues’ trial.
Tedizolid Dosing forms & strength: tablet 200mg. Lyophilized powder for reconstitution 200mg/vial.
Indication: for acute bacterial Skin and skin structure infections.
Mechanism of action: Tedizolid phosphate is the prodrug of tedizolid. It performs it’s action by binding to the 50S subunit of bacterial ribosome, and inhibits protein synthesis.
Reference: The Lancet Infectious Diseases, Volume 14, issue 8.